| Symbol | AUTL |
|---|---|
| Name | AUTOLUS THERAPEUTICS PLC |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 191 WOOD LANE,THE MEDIAWORKS, LONDON, W12 7FP, United Kingdom |
| Telephone | +44 2038296230 |
| Fax | — |
| — | |
| Website | https://www.autolus.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001730463 |
| Description | Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. The companys clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Additional info from NASDAQ: |
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
Read morePiccina Cintia 🟡 adjusted position in 6.7K shares (1 derivative) of Autolus Therapeutics plc (AUTL) at $2.35 Transaction Date: Sep 01, 2026 | Filing ID: 000131
Read more📋 Piccina Cintia (Officer) plans to sell 7K shares of Autolus Therapeutics plc (at $2.34 each, total $16K) Filed: Sep 02, 2026 | ID: 006649
Read moreNew Form SCHEDULE 13D/A - Autolus Therapeutics plc <b>Filed:</b> 2026-08-28 <b>AccNo:</b> 0001213900-26-095283 <b>Size:</b> 39 KB
Read moreNew Form SCHEDULE 13G/A - Autolus Therapeutics plc <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003552 <b>Size:</b> 10 KB
Read more(90% Positive) AUTOLUS THERAPEUTICS PLC (AUTL) Announces Enrollment Update for growth Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreAutolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Read moreAutolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026
Read moreAutolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors
Read moreDirector BUTITTA CYNTHIA M 🟢 acquired 79.2K shares (2 derivative) of Autolus Therapeutics plc (AUTL) at $1.61 Transaction Date: Jun 29, 2026 | Filing ID: 000097
Read more